
|Podcasts|July 26, 2021
Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment
Author(s)Elizabeth Yeu, MD, Alex Delaney-Gesing
Elizabeth Yeu, MD, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of TP03 for the treatment of patients diagnosed with Demodex blepharitis.
Advertisement
Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants, shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial
2
Retina Society 2026: SOL-1 shows intravitreal axitinib hydrogel superior to aflibercept in wet AMD
3
Retina Society 2026: Ocular syphilis, HIV co-infection, and RPR titers
4
Retina Society 2026: How blood biomarkers may predict GA speed
5











